Roche Dx Licenses Multilyte’s Multiparameter Binding Assay IP | GenomeWeb
NEW YORK (GenomeWeb News) - Roche Diagnostics today said it has signed a licensing agreement with Multilyte for access to Multilyte's patents for diagnostic assays.
 
Roche will pay a license fee and royalties from the sale of products covered by Multilyte’s patents.
 
Assays covered under the patents include mulitparameter binding assays, including immunoassays, to enable “simultaneous detection and analysis of many different analytes in small test samples of biological origin,” Roche said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.